1668 related articles for article (PubMed ID: 25873496)
41. Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms.
Cacemiro MDC; Cominal JG; Pereira LM; Berzoti-Coelho MG; Berbel GM; Baroni L; Malta T; Tognon R; Nunes NS; Souto EX; de Figueiredo-Pontes LL; Yatsuda AP; de Castro FA
Med Oncol; 2022 May; 39(5):97. PubMed ID: 35599283
[TBL] [Abstract][Full Text] [Related]
42. Prevalence of MPL W515L/K mutations in Taiwanese patients with Philadelphia-negative chronic myeloproliferative neoplasms.
Lieu CH; Shen YJ; Lai WC; Tsai WH; Hsu HC
J Chin Med Assoc; 2010 Oct; 73(10):530-2. PubMed ID: 21051030
[TBL] [Abstract][Full Text] [Related]
43. Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation.
Hermouet S; Bigot-Corbel E; Gardie B
Mediators Inflamm; 2015; 2015():145293. PubMed ID: 26538820
[TBL] [Abstract][Full Text] [Related]
44. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.
Andrikovics H; Krahling T; Balassa K; Halm G; Bors A; Koszarska M; Batai A; Dolgos J; Csomor J; Egyed M; Sipos A; Remenyi P; Tordai A; Masszi T
Haematologica; 2014 Jul; 99(7):1184-90. PubMed ID: 24895336
[TBL] [Abstract][Full Text] [Related]
45. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia.
Chen CC; Gau JP; Chou HJ; You JY; Huang CE; Chen YY; Lung J; Chou YS; Leu YW; Lu CH; Lee KD; Tsai YH
Ann Hematol; 2014 Dec; 93(12):2029-36. PubMed ID: 25015052
[TBL] [Abstract][Full Text] [Related]
46. [Expression level of Wilms' tumor 1 gene and its correlation with clinical features in patients with myeloproliferative neoplasms].
Liu C; Wu SY; Zhang AB; Luo P; Zhou Y; Liu Y; Zuo XL
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3658-3664. PubMed ID: 38018065
[No Abstract] [Full Text] [Related]
47. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.
Tefferi A; Thiele J; Vannucchi AM; Barbui T
Leukemia; 2014 Jul; 28(7):1407-13. PubMed ID: 24441292
[TBL] [Abstract][Full Text] [Related]
48. Life, genes, and death in Ph- MPNs.
Silver RT
Blood; 2014 Oct; 124(16):2471-2. PubMed ID: 25323682
[TBL] [Abstract][Full Text] [Related]
49. The differences of hemogram, myelogram, and driver gene mutations in classic myeloproliferative neoplasms.
Wang J; Zhang J; Huang J; Mei Y; Hong Z
Blood Cells Mol Dis; 2022 Nov; 97():102698. PubMed ID: 35914897
[TBL] [Abstract][Full Text] [Related]
50. Clinical laboratory characteristics and gene mutation spectrum of Ph-negative MPN patients with atypical variants of JAK2, MPL, or CALR.
Wang Z; Tian X; Ma J; Zhang Y; Ta W; Duan Y; Li F; Zhang H; Chen L; Yang S; Liu E; Lin Y; Yuan W; Ru K; Bai J
Cancer Med; 2024 Apr; 13(7):e7123. PubMed ID: 38618943
[TBL] [Abstract][Full Text] [Related]
51. [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].
Yan X; Qin TJ; Li B; Qu SQ; Pan LJ; Li FH; Liu NN; Xiao ZJ; Xu ZF
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):276-283. PubMed ID: 37356995
[No Abstract] [Full Text] [Related]
52. MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.
Yasuda S; Aoyama S; Yoshimoto R; Li H; Watanabe D; Akiyama H; Yamamoto K; Fujiwara T; Najima Y; Doki N; Sakaida E; Edahiro Y; Imai M; Araki M; Komatsu N; Miura O; Kawamata N
Int J Hematol; 2021 Oct; 114(4):424-440. PubMed ID: 34165774
[TBL] [Abstract][Full Text] [Related]
53. A rare CALR variant mutation and efficient peginterferon alfa-2a response in a patient with essential thrombocythemia.
Ciftciler R; Balasar O
Cancer Genet; 2023 Jun; 274-275():51-53. PubMed ID: 36972657
[TBL] [Abstract][Full Text] [Related]
54. Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study.
England JT; Szuber N; Sirhan S; Dunne T; Cerquozzi S; Hill M; Villeneuve PJA; Ho JM; Sadikovic B; Bhai P; Krishnan N; Dowhanik S; Hillis C; Capo-Chichi JM; Tsui H; Cheung V; Gauthier K; Sibai H; Davidson MB; Bankar A; Kotchetkov R; Gupta V; Maze D
Leukemia; 2024 Mar; 38(3):570-578. PubMed ID: 38321107
[TBL] [Abstract][Full Text] [Related]
55.
Sassi H; Menif S; Ammar SB; Farrah A; Othmen HBH; Amouri H
Pan Afr Med J; 2021; 39():194. PubMed ID: 34603575
[TBL] [Abstract][Full Text] [Related]
56. Increase in Frequency of Myeloid-Derived Suppressor Cells in the Bone Marrow of Myeloproliferative Neoplasm: Potential Implications in Myelofibrosis.
Kapor S; Momčilović S; Kapor S; Mojsilović S; Radojković M; Apostolović M; Filipović B; Gotić M; Čokić V; Santibanez JF
Adv Exp Med Biol; 2023; 1408():273-290. PubMed ID: 37093433
[TBL] [Abstract][Full Text] [Related]
57. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.
Ha JS; Kim YK; Jung SI; Jung HR; Chung IS
Ann Lab Med; 2012 Nov; 32(6):385-91. PubMed ID: 23130336
[TBL] [Abstract][Full Text] [Related]
58. [Clinical and genetic characteristics of young patients with myeloproliferative neoplasms].
Zhang MY; Bao M; Shi DY; Shi HX; Liu XL; Xu N; Duan MH; Zhuang JL; Du X; Qin L; Hui WH; Liang R; Wang MF; Chen Y; Li DY; Yang W; Tang GS; Zhang WH; Kuang X; Su W; Han YQ; Chen LM; Xu JH; Liu ZG; Huang J; Zhao CT; Tong HY; Hu JD; Chen CY; Chen XQ; Xiao ZJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):193-201. PubMed ID: 37356980
[No Abstract] [Full Text] [Related]
59. Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations.
Millecker L; Lennon PA; Verstovsek S; Barkoh B; Galbincea J; Hu P; Chen SS; Jones D
Cancer Genet Cytogenet; 2010 Feb; 197(1):1-7. PubMed ID: 20113830
[TBL] [Abstract][Full Text] [Related]
60. Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, CALR and MPL mutations.
Langabeer SE; Haslam K; Linders J; Percy MJ; Conneally E; Hayat A; Hennessy B; Leahy M; Murphy K; Murray M; Ni Ainle F; Thornton P; Sargent J
Fam Cancer; 2014 Dec; 13(4):659-63. PubMed ID: 25103330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
